somerset pharmaceuticals, inc. , a wholly owned subsidiary of mylan inc. ,
received approval from the fda for emsam® transdermal
selegiline, on february 27 of 2006. Emsam® is the
first transdermal treatment for major depressive disorder. All aspects of the
emsam® product related to its design, chemistry,
manufacturing and controls were the result of the integration of the talents
and expertise of mti scientists. Emsam® is
manufactured by mti.
antidepressants increased the risk of suicidal thinking and behavior
(suicidality) in short-term studies in children and adolescents with major
depressive disorder (mdd) and other psychotic disorders. Anyone considering the
use of emsam® or other antidepressants in a child or
adolescent must balance this risk with the clinical need.
emsam® is not indicated for use in pediatric patients.
for additional details please see full prescribing information, including boxed
TOVEX COALMINER permissible water gel is multipurpose small diameter cartridge explosive, specially designed for though loading and shooting ...view details
Molecular formula:HNO3 Molecular weight:63.01 CAS NO.:7697-37-2 Property:Pure nitric acid is colorless liquid with pungent odor,it's density is ...view details
high purity 99.9% Epichlorohydrin Properity it is the unstable colorless liquid,easy to volatilize, has with the chloroform, the ether similar ...view details
sending enquiry ....